NASDAQ:PROK

ProKidney (PROK) Stock Forecast, Price & News

$4.32

0.00 (0.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: $3.95
▼
$4.34
50-Day Range: $4.32
▼
$13.08
52-Week Range: $3.95
▼
$14.19

Volume: 726,426 shs
Average Volume: 290,645 shs
Market Capitalization: $1.02 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.60

ProKidney MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 261.1% Upside
$15.60 Price Target
Short Interest: Bearish
38.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 5 Articles This Week
Insider Trading: Selling Shares
$9.30 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.20) to ($1.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

872nd out of 976 stocks

Biological Products, Except Diagnostic Industry

145th out of 159 stocks

3.4

Analyst's Opinion

Consensus Rating
ProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.60, ProKidney has a forecasted upside of 261.1% from its current price of $4.32.
Amount of Analyst Coverage
ProKidney has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
38.47% of the float of ProKidney has been sold short.
Short Interest Ratio / Days to Cover
ProKidney has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.
Change versus previous month
Short interest in ProKidney has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ProKidney does not currently pay a dividend.
Dividend Growth
ProKidney does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PROK.

2.3

News and Social Media Coverage

News Sentiment
ProKidney has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ProKidney this week, compared to 1 article on an average week.
Search Interest
6 people have searched for PROK on MarketBeat in the last 30 days.
MarketBeat Follows
Only 5 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,299,000.00 in company stock.
Percentage Held by Insiders
44.99% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 16.94% of the stock of ProKidney is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ProKidney are expected to decrease in the coming year, from ($1.20) to ($1.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProKidney is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProKidney is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About ProKidney (NASDAQ:PROK) Stock

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Price History

30 days | 90 days | 365 days | Advanced Chart

PROK Stock News Headlines

September 24, 2023 | americanbankingnews.com

ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume

September 23, 2023 | americanbankingnews.com

Chamath Palihapitiya Sells 1,700,000 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

September 28, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 22, 2023 | benzinga.com

ProKidney 10% Owner Trades $9.30M In Company Stock

September 13, 2023 | seekingalpha.com

REACT Or Retreat: ProKidney's Phase 3 Focal Point

September 6, 2023 | finance.yahoo.com

ProKidney confirms it will expand HQ complex, add 50 jobs in Winston-Salem

September 5, 2023 | finance.yahoo.com

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

August 31, 2023 | bizjournals.com

ProKidney gets Forsyth County's OK for incentives to expand HQ in Winston-Salem

September 28, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 29, 2023 | finance.yahoo.com

ProKidney confirmed as company seeking incentives to expand in Forsyth County

August 15, 2023 | bizjournals.com

Nearly 330 jobs tied to pair of incentives sought by two companies in Winston-Salem

August 11, 2023 | finance.yahoo.com

ProKidney reports $38.8 million loss in Q2 FY2023 as it advances clinical trials and prepares for Greensboro manufacturing expansion

August 11, 2023 | finance.yahoo.com

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

July 26, 2023 | msn.com

BTIG Initiates Coverage of ProKidney Corp - (PROK) with Buy Recommendation

July 18, 2023 | bizjournals.com

ProKidney closes on Greensboro site for commercialization

July 18, 2023 | finance.yahoo.com

ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC

July 17, 2023 | bizjournals.com

ProKidney appoints Dr. Bruce Culleton as executive VP of clinical development and commercialization

July 17, 2023 | finance.yahoo.com

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

July 12, 2023 | bizjournals.com

Q&A with Greensboro's Marvin Price, the NC economic developer of the year

July 4, 2023 | benzinga.com

Board Member at ProKidney Acquires Company Stock Options Worth 48,128 Shares

July 3, 2023 | benzinga.com

ProKidney Board Member Awarded $537K Worth of Stock Options

July 3, 2023 | benzinga.com

ProKidney Director Awarded $537K Worth of Stock Options

June 14, 2023 | bizjournals.com

ProKidney manufacturing: The one that didn't get away

June 14, 2023 | news.yahoo.com

Major biomanufacturing project slated for Triad

June 14, 2023 | bizjournals.com

ProKidney wins North Carolina incentives for $458M, 330-job manufacturing plant in Greensboro

June 14, 2023 | bizjournals.com

ProKidney wins NC incentives, plans $458M manufacturing facility with 330 jobs in Greensboro

June 13, 2023 | msn.com

Biomanufacturing facility aiming to treat chronic kidney disease coming to Guilford County

See More Headlines

Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

PROK Company Calendar

Last Earnings: 8/10/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PROK
CUSIP: N/A
CIK: 1850270
Web: www.prokidney.com
Phone: 336-999-7028
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.60
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +261.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -7.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.04
Quick Ratio: 19.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($42.77) per share
Price / Book: -0.10

Miscellaneous

Outstanding Shares: 235,130,000
Free Float: 129,344,000
Market Cap: $1.02 billion
Optionable: Not Optionable
Beta: N/A

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Timothy A. Bertram D.V.M. (Age 68)
Ph.D., Founder, CEO & Director
Comp: $970.4k

Dr. Deepak Jain Ph.D. (Age 69)
Chief Operating Officer
Comp: $768.65k

Mr. Todd C. Girolamo Esq. (Age 58)
J.D., M.B.A., Chief Legal Officer & Corp. Sec.
Comp: $600.17k

Mr. James Coulston CPA (Age 47)
Chief Financial Officer

Dr. Glenn Schulman M.P.H.
Pharm. D., Pharm.D., Sr. VP of Investor Relations

Ms. Mary Weger (Age 64)
Chief People Officer

Ms. Ashley H. Johns
Sr. VP & Head of Global Clinical Operations

Dr. Joseph M. Stavas M.D.
M.P.H., Sr. VP and Head of Global Clinical Devel. & Interventional Procedures

Dr. Darin J. Weber Ph.D. (Age 55)
Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access

Dr. Bruce Culleton M.D.
Exec. VP of Clinical Devel. & Commercialization

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PROK Stock - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PROK shares.
View PROK analyst ratings or view top-rated stocks.
What is ProKidney's stock price forecast for 2023?: 5 Wall Street analysts have issued 1 year price targets for ProKidney's shares. Their PROK share price forecasts range from $13.00 to $18.00. On average, they anticipate the company's share price to reach $15.60 in the next year. This suggests a possible upside of 261.1% from the stock's current price.
View analysts price targets for PROK or view top-rated stocks among Wall Street analysts.
How have PROK shares performed in 2023?: ProKidney's stock was trading at $6.86 at the beginning of the year. Since then, PROK shares have decreased by 37.0% and is now trading at $4.32.
View the best growth stocks for 2023 here.
When is ProKidney's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PROK earnings forecast.
How were ProKidney's earnings last quarter?: ProKidney Corp. (NASDAQ:PROK) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.27.
What ETF holds ProKidney's stock ?: ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.

What is ProKidney's stock symbol?: ProKidney trades on the NASDAQ under the ticker symbol "PROK."
Who are ProKidney's major shareholders?: ProKidney's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.41%), State Street Corp (0.42%), Geode Capital Management LLC (0.32%), Northern Trust Corp (0.19%), Nuveen Asset Management LLC (0.09%) and Nuveen Asset Management LLC (0.09%).
View institutional ownership trends.
How do I buy shares of ProKidney?: Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ProKidney's stock price today?: One share of PROK stock can currently be purchased for approximately $4.32.
How much money does ProKidney make?: ProKidney (NASDAQ:PROK) has a market capitalization of $1.02 billion. The company earns $-108,030,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.
How can I contact ProKidney?: ProKidney's mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The official website for the company is www.prokidney.com. The company can be reached via phone at 336-999-7028 or via email at lroth@burnsmc.com.

This page (NASDAQ:PROK) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ProKidney (PROK) Stock Forecast, Price & News

ProKidney MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ProKidney (NASDAQ:PROK) Stock

PROK Price History

PROK Stock News Headlines

PROK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PROK Stock - Frequently Asked Questions

Overall MarketRank^™